{"id":999441,"date":"2026-09-01T12:57:56","date_gmt":"2026-09-01T16:57:56","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aardvark-therapeutics-inc-aard-investors-with-substantial-losses-have-opportunity-to-lead-aardvark-class-action-lawsuit-before-october-13-deadline\/"},"modified":"2026-09-01T12:57:56","modified_gmt":"2026-09-01T16:57:56","slug":"aardvark-therapeutics-inc-aard-investors-with-substantial-losses-have-opportunity-to-lead-aardvark-class-action-lawsuit-before-october-13-deadline","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aardvark-therapeutics-inc-aard-investors-with-substantial-losses-have-opportunity-to-lead-aardvark-class-action-lawsuit-before-october-13-deadline\/","title":{"rendered":"Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 Deadline"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\">SAN FRANCISCO<\/span>, <span class=\"legendSpanClass\">Sept. 1, 2026<\/span> \/PRNewswire\/ &#8212; Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (<b>NASDAQ: AARD<\/b>) of a pending securities class action lawsuit.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <img decoding=\"async\" src=\"https:\/\/mmx.prnewswire.com\/media\/MS1117217\/Hagens-Berman-Sobol-Shapiro-LLP-Logo.jpg?id=OA2923190\" title=\"Class Action\" alt=\"Class Action\" \/>\n        <\/p>\n<\/p><\/div>\n<p>Investors who purchased or acquired Aardvark common stock pursuant and\/or traceable to the offering documents issued in connection with the Company&#8217;s initial public offering (<b>IPO<\/b>) on or about <b>February 13, 2025<\/b>, and\/or purchased or acquired Aardvark securities between <b>February 13, 2025 and May 14, 2026<\/b>\u00a0(the <b>Class Period<\/b>), are encouraged to <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4764879-1&amp;h=130381353&amp;u=https%3A%2F%2Fwww.hbsslaw.com%2Fcases%2Faardvark-therapeutics-inc-aard-securities-class-action&amp;a=contact+our+firm+now\" target=\"_blank\" rel=\"nofollow\">contact our firm now<\/a>.<\/p>\n<p>\n        <b>Key Case Details &amp; Important Deadlines<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <b>Lead Plaintiff Motion Deadline:<\/b>\u00a0<b>October 13, 2026<\/b>\u00a0<\/li>\n<li>\n          <b>Visit:<\/b>\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4764879-1&amp;h=3427610995&amp;u=https%3A%2F%2Fwww.hbsslaw.com%2Fcases%2Faardvark-therapeutics-inc-aard-securities-class-action&amp;a=www.hbsslaw.com%2Faard\" target=\"_blank\" rel=\"nofollow\">www.hbsslaw.com\/aard<\/a>\u00a0<\/li>\n<li>\n          <b>Contact the Firm Now: <\/b><br \/>\n          <a href=\"mailto:AARD@hbsslaw.com\" target=\"_blank\" rel=\"nofollow\">AARD@hbsslaw.com<\/a><br \/>\n          <br \/>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0844-916-0895<\/li>\n<\/ul>\n<p>\n        <b>What is the Lawsuit About?<\/b>\n      <\/p>\n<p>The complaint <span>alleges<\/span> that Aardvark Therapeutics, a clinical-stage biopharmaceutical company focused on developing small-molecule therapies targeting bitter taste receptors (TAS2Rs) such as ARD-101 for the treatment of hyperphagia in Prader-Willi Syndrome (PWS), made materially false and misleading statements and\/or failed to disclose critical information.<\/p>\n<p>Specifically, the action points out that the offering documents and defendants failed to disclose:<\/p>\n<ol type=\"1\">\n<li>That <b>ARD-101<\/b>\u00a0was significantly less safe than defendants had led investors to believe;<\/li>\n<li>That unexpected, reversible cardiac observations (such as QRS prolongation) occurred during trials at above-target doses; and<\/li>\n<li>Consequently, Aardvark&#8217;s clinical, regulatory, and commercial prospects\u2014including the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial and open-label extension (OLE)\u2014were materially overstated.<\/li>\n<\/ol>\n<p>\n        <b>The Truth Emerges: Voluntarily Pause and FDA Clinical Hold<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <b>February 27, 2026<\/b>: Aardvark announced it was voluntarily pausing its Phase 3 HERO trial due to &#8220;reversible cardiac observations at above target therapeutic doses found during routine safety monitoring in a healthy volunteer study.&#8221; Following this news, Aardvark&#8217;s stock price plummeted over <b>56%<\/b>.\u00a0<\/li>\n<li>\n          <b>May 14, 2026<\/b>:\u00a0 Aardvark announced that the U.S. Food and Drug Administration (FDA) placed a full clinical hold on its investigational new drug application (IND) for ARD-101, halting all ongoing studies under the IND, including the Phase 3 HERO trial and OLE trial. Aardvark&#8217;s stock price fell another <b>32.1%<\/b>.<\/li>\n<\/ul>\n<p>\n        <b>Hagens Berman&#8217;s Investigation<\/b>\n      <\/p>\n<p>&#8220;We&#8217;re investigating the suit&#8217;s allegations, including that Aardvark <span>allegedly<\/span> misled investors about ARD-101&#8217;s development, its safety and efficacy,&#8221; said <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4764879-1&amp;h=976505646&amp;u=https%3A%2F%2Fwww.hbsslaw.com%2Fattorneys%2Freed-kathrein&amp;a=Reed+Kathrein\" target=\"_blank\" rel=\"nofollow\"><b>Reed Kathrein<\/b><\/a>, the Hagens Berman partner leading the firm&#8217;s investigation of the claims in the pending suit.<\/p>\n<p>\n        <b>What Can Aardvark Investors Do?<\/b>\n      <\/p>\n<p>If you are a class member who suffered losses on Aardvark securities, you have until <b>October 13, 2026<\/b>, to ask the Court to appoint you as Lead Plaintiff for the class.\u00a0 The firm welcomes AARD investors to contact the firm to discuss their legal rights and potential recovery options.<\/p>\n<ul type=\"disc\">\n<li>\n          <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4764879-1&amp;h=3172332611&amp;u=https%3A%2F%2Fwww.hbsslaw.com%2Fcases%2Faardvark-therapeutics-inc-aard-securities-class-action&amp;a=Submit+Your+Information+to+Hagens+Berman\" target=\"_blank\" rel=\"nofollow\">Submit Your Information to Hagens Berman<\/a>\n        <\/li>\n<li>\n          <b>Contact an Attorney: <\/b><br \/>\n          <a href=\"mailto:AARD@hbsslaw.com\" target=\"_blank\" rel=\"nofollow\">AARD@hbsslaw.com<\/a><br \/>\n          <br \/>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 844-916-0895<\/li>\n<\/ul>\n<p>If you&#8217;d like more information and answers to frequently asked questions about the firm&#8217;s Aardvark investigation, <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4764879-1&amp;h=1643080268&amp;u=https%3A%2F%2Fwww.hbsslaw.com%2Fcases%2Faardvark-therapeutics-inc-aard-securities-class-action&amp;a=read+more%C2%A0%C2%BB\" target=\"_blank\" rel=\"nofollow\">read more\u00a0\u00bb<\/a><\/p>\n<p>\n        <b>Whistleblowers: <\/b>Persons with non-public information regarding Aardvark Therapeutics should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at <b>844-916-0895<\/b>\u00a0or email <a href=\"mailto:AARD@hbsslaw.com\" target=\"_blank\" rel=\"nofollow\">AARD@hbsslaw.com<\/a>.<\/p>\n<p>\n        <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4764879-1&amp;h=3986041575&amp;u=https%3A%2F%2Fwww.hbsslaw.com%2F&amp;a=About%C2%A0Hagens+Berman\" target=\"_blank\" rel=\"nofollow\">About\u00a0Hagens Berman<\/a><br \/>\n        <br \/>Hagens Berman is a global plaintiffs&#8217; rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate <span>negligence<\/span> and other wrongdoings. Hagens Berman&#8217;s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4764879-1&amp;h=1147065459&amp;u=https%3A%2F%2Fwww.hbsslaw.com%2F&amp;a=hbsslaw.com\" target=\"_blank\" rel=\"nofollow\">hbsslaw.com<\/a>. Follow the firm for updates and news at\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4764879-1&amp;h=2126715773&amp;u=https%3A%2F%2Fwww.twitter.com%2FClassActionLaw&amp;a=%40ClassActionLaw\" target=\"_blank\" rel=\"nofollow\">@ClassActionLaw<\/a>.\u00a0<\/p>\n<p>Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=SF38163&amp;sd=2026-09-01\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/aardvark-therapeutics-inc-aard-investors-with-substantial-losses-have-opportunity-to-lead-aardvark-class-action-lawsuit-before-october-13-deadline-302866532.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/aardvark-therapeutics-inc-aard-investors-with-substantial-losses-have-opportunity-to-lead-aardvark-class-action-lawsuit-before-october-13-deadline-302866532.html<\/a><\/p>\n<p>SOURCE Hagens Berman Sobol Shapiro LLP<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=SF38163&amp;Transmission_Id=202609011237PR_NEWS_USPR_____SF38163&amp;DateId=20260901\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire SAN FRANCISCO, Sept. 1, 2026 \/PRNewswire\/ &#8212; Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit. Investors who purchased or acquired Aardvark common stock pursuant and\/or traceable to the offering documents issued in connection with the Company&#8217;s initial public offering (IPO) on or about February 13, 2025, and\/or purchased or acquired Aardvark securities between February 13, 2025 and May 14, 2026\u00a0(the Class Period), are encouraged to contact our firm now. Key Case Details &amp; Important Deadlines Lead Plaintiff Motion Deadline:\u00a0October 13, 2026\u00a0 Visit:\u00a0www.hbsslaw.com\/aard\u00a0 Contact the Firm Now: AARD@hbsslaw.com \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aardvark-therapeutics-inc-aard-investors-with-substantial-losses-have-opportunity-to-lead-aardvark-class-action-lawsuit-before-october-13-deadline\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 Deadline&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-999441","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 Deadline - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aardvark-therapeutics-inc-aard-investors-with-substantial-losses-have-opportunity-to-lead-aardvark-class-action-lawsuit-before-october-13-deadline\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 Deadline - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN FRANCISCO, Sept. 1, 2026 \/PRNewswire\/ &#8212; Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit. Investors who purchased or acquired Aardvark common stock pursuant and\/or traceable to the offering documents issued in connection with the Company&#8217;s initial public offering (IPO) on or about February 13, 2025, and\/or purchased or acquired Aardvark securities between February 13, 2025 and May 14, 2026\u00a0(the Class Period), are encouraged to contact our firm now. Key Case Details &amp; Important Deadlines Lead Plaintiff Motion Deadline:\u00a0October 13, 2026\u00a0 Visit:\u00a0www.hbsslaw.com\/aard\u00a0 Contact the Firm Now: AARD@hbsslaw.com \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 &hellip; Continue reading &quot;Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 Deadline&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aardvark-therapeutics-inc-aard-investors-with-substantial-losses-have-opportunity-to-lead-aardvark-class-action-lawsuit-before-october-13-deadline\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-01T16:57:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mmx.prnewswire.com\/media\/MS1117217\/Hagens-Berman-Sobol-Shapiro-LLP-Logo.jpg?id=OA2923190\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aardvark-therapeutics-inc-aard-investors-with-substantial-losses-have-opportunity-to-lead-aardvark-class-action-lawsuit-before-october-13-deadline\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aardvark-therapeutics-inc-aard-investors-with-substantial-losses-have-opportunity-to-lead-aardvark-class-action-lawsuit-before-october-13-deadline\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 Deadline\",\"datePublished\":\"2026-09-01T16:57:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aardvark-therapeutics-inc-aard-investors-with-substantial-losses-have-opportunity-to-lead-aardvark-class-action-lawsuit-before-october-13-deadline\\\/\"},\"wordCount\":656,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aardvark-therapeutics-inc-aard-investors-with-substantial-losses-have-opportunity-to-lead-aardvark-class-action-lawsuit-before-october-13-deadline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1117217\\\/Hagens-Berman-Sobol-Shapiro-LLP-Logo.jpg?id=OA2923190\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aardvark-therapeutics-inc-aard-investors-with-substantial-losses-have-opportunity-to-lead-aardvark-class-action-lawsuit-before-october-13-deadline\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aardvark-therapeutics-inc-aard-investors-with-substantial-losses-have-opportunity-to-lead-aardvark-class-action-lawsuit-before-october-13-deadline\\\/\",\"name\":\"Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 Deadline - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aardvark-therapeutics-inc-aard-investors-with-substantial-losses-have-opportunity-to-lead-aardvark-class-action-lawsuit-before-october-13-deadline\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aardvark-therapeutics-inc-aard-investors-with-substantial-losses-have-opportunity-to-lead-aardvark-class-action-lawsuit-before-october-13-deadline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1117217\\\/Hagens-Berman-Sobol-Shapiro-LLP-Logo.jpg?id=OA2923190\",\"datePublished\":\"2026-09-01T16:57:56+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aardvark-therapeutics-inc-aard-investors-with-substantial-losses-have-opportunity-to-lead-aardvark-class-action-lawsuit-before-october-13-deadline\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aardvark-therapeutics-inc-aard-investors-with-substantial-losses-have-opportunity-to-lead-aardvark-class-action-lawsuit-before-october-13-deadline\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aardvark-therapeutics-inc-aard-investors-with-substantial-losses-have-opportunity-to-lead-aardvark-class-action-lawsuit-before-october-13-deadline\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1117217\\\/Hagens-Berman-Sobol-Shapiro-LLP-Logo.jpg?id=OA2923190\",\"contentUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1117217\\\/Hagens-Berman-Sobol-Shapiro-LLP-Logo.jpg?id=OA2923190\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aardvark-therapeutics-inc-aard-investors-with-substantial-losses-have-opportunity-to-lead-aardvark-class-action-lawsuit-before-october-13-deadline\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 Deadline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 Deadline - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aardvark-therapeutics-inc-aard-investors-with-substantial-losses-have-opportunity-to-lead-aardvark-class-action-lawsuit-before-october-13-deadline\/","og_locale":"en_US","og_type":"article","og_title":"Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 Deadline - Market Newsdesk","og_description":"PR Newswire SAN FRANCISCO, Sept. 1, 2026 \/PRNewswire\/ &#8212; Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit. Investors who purchased or acquired Aardvark common stock pursuant and\/or traceable to the offering documents issued in connection with the Company&#8217;s initial public offering (IPO) on or about February 13, 2025, and\/or purchased or acquired Aardvark securities between February 13, 2025 and May 14, 2026\u00a0(the Class Period), are encouraged to contact our firm now. Key Case Details &amp; Important Deadlines Lead Plaintiff Motion Deadline:\u00a0October 13, 2026\u00a0 Visit:\u00a0www.hbsslaw.com\/aard\u00a0 Contact the Firm Now: AARD@hbsslaw.com \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 &hellip; Continue reading \"Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 Deadline\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aardvark-therapeutics-inc-aard-investors-with-substantial-losses-have-opportunity-to-lead-aardvark-class-action-lawsuit-before-october-13-deadline\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-01T16:57:56+00:00","og_image":[{"url":"https:\/\/mmx.prnewswire.com\/media\/MS1117217\/Hagens-Berman-Sobol-Shapiro-LLP-Logo.jpg?id=OA2923190","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aardvark-therapeutics-inc-aard-investors-with-substantial-losses-have-opportunity-to-lead-aardvark-class-action-lawsuit-before-october-13-deadline\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aardvark-therapeutics-inc-aard-investors-with-substantial-losses-have-opportunity-to-lead-aardvark-class-action-lawsuit-before-october-13-deadline\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 Deadline","datePublished":"2026-09-01T16:57:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aardvark-therapeutics-inc-aard-investors-with-substantial-losses-have-opportunity-to-lead-aardvark-class-action-lawsuit-before-october-13-deadline\/"},"wordCount":656,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aardvark-therapeutics-inc-aard-investors-with-substantial-losses-have-opportunity-to-lead-aardvark-class-action-lawsuit-before-october-13-deadline\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1117217\/Hagens-Berman-Sobol-Shapiro-LLP-Logo.jpg?id=OA2923190","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aardvark-therapeutics-inc-aard-investors-with-substantial-losses-have-opportunity-to-lead-aardvark-class-action-lawsuit-before-october-13-deadline\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aardvark-therapeutics-inc-aard-investors-with-substantial-losses-have-opportunity-to-lead-aardvark-class-action-lawsuit-before-october-13-deadline\/","name":"Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 Deadline - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aardvark-therapeutics-inc-aard-investors-with-substantial-losses-have-opportunity-to-lead-aardvark-class-action-lawsuit-before-october-13-deadline\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aardvark-therapeutics-inc-aard-investors-with-substantial-losses-have-opportunity-to-lead-aardvark-class-action-lawsuit-before-october-13-deadline\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1117217\/Hagens-Berman-Sobol-Shapiro-LLP-Logo.jpg?id=OA2923190","datePublished":"2026-09-01T16:57:56+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aardvark-therapeutics-inc-aard-investors-with-substantial-losses-have-opportunity-to-lead-aardvark-class-action-lawsuit-before-october-13-deadline\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aardvark-therapeutics-inc-aard-investors-with-substantial-losses-have-opportunity-to-lead-aardvark-class-action-lawsuit-before-october-13-deadline\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aardvark-therapeutics-inc-aard-investors-with-substantial-losses-have-opportunity-to-lead-aardvark-class-action-lawsuit-before-october-13-deadline\/#primaryimage","url":"https:\/\/mmx.prnewswire.com\/media\/MS1117217\/Hagens-Berman-Sobol-Shapiro-LLP-Logo.jpg?id=OA2923190","contentUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1117217\/Hagens-Berman-Sobol-Shapiro-LLP-Logo.jpg?id=OA2923190"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aardvark-therapeutics-inc-aard-investors-with-substantial-losses-have-opportunity-to-lead-aardvark-class-action-lawsuit-before-october-13-deadline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 Deadline"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/999441","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=999441"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/999441\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=999441"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=999441"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=999441"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}